The PDE-4 inhibitor apremilast (Otezla) is now available on the PBS for the treatment of severe chronic plaque psoriasis in patients who have failed treatment with or who are contraindicated or intolerant to methotrexate. The listing, which comes into effect from 1 January will allow more 5000 people to gain access to the treatment which ...
Apremilast gets PBS listing for psoriasis, but eczema therapies face uncertainty
By Michael Woodhead
19 Jan 2021